All In Biotech

NDA 203975 · Glaxosmithkline

Anoro Ellipta

Umeclidinium Bromide, Vilanterol Trifenatate · Inhalation

Novel

Last checked: Nov 20, 2026Latest source record: Jun 2, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Dec 18, 2013

Approved uses

2

Original approval plus efficacy supplements

Registered trials

103

39 Phase 3, 4 recruiting

FAERS reports

16,834

5,911 serious, 856 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 22, 2024.

Umeclidinium and Vilanterol ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use Umeclidinium and Vilanterol ELLIPTA is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma. The safety and effectiveness of Umeclidinium and Vilanterol ELLIPTA in asthma have not been established. Umeclidinium and Vilanterol ELLIPTA is a combination of umeclidinium, an anticholinergic, and vilanterol, a long-acting beta 2 -adrenergic agonist (LABA), indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1 ) Limitations of Use: Not indicated for relief of acute bronchospasm or for the treatment of asthma. ( 1 , 5.2 )

Mechanism: Umeclidinium and Vilanterol ELLIPTA Umeclidinium and Vilanterol ELLIPTA contains both umeclidinium and vilanterol. The mechanisms of action described below for the individual components apply to Umeclidinium and Vilanterol ELLIPTA. These drugs represent 2 different classes of medications (an anticholinergic and a LABA) each having different effects on clinical and physiological indices. Umeclidinium Umeclidinium is a long-acting muscarinic antagonist, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ANORO ELLIPTA · UMECLIDINIUM BROMIDE EQ 0.0625MG BASE/INH; VILANTEROL TRIFENATATE EQ 0.025MG BASE/INH · POWDER, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Umeclidinium" as an intervention, any sponsor and status, largest first.

All 103 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea2,391
  • wrong technique in device usage process1,681
  • drug ineffective1,639
  • product complaint1,219
  • cough1,116
  • product dose omission issue930
  • pneumonia684
  • chronic obstructive pulmonary disease637
  • condition aggravated521
  • drug dispensing error496
  • off label use491
  • death478

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20121
20135
2014267
20151,005
20161,554
20171,660
20182,336
20192,296
20202,026
20211,290
2022981
2023947
2024981
2025926
2026559

Recalls

1 FDA enforcement reports for this application.

  • Dec 12, 2023 · Class III · Terminated

    Failed Release Testing: Coarse Particle Mass for umeclidinium Out of Specification

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Anoro Ellipta (Umeclidinium Brm/Vilanterol Tr)

2024 spending

$819M

Beneficiaries

291,195

1,383,988 claims

Per beneficiary

$2,813

$7.58 per unit

View as table
YearSpending
2020$1,002,343,776
2021$912,370,402
2022$866,849,124
2023$872,959,570
2024$819,257,998

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 144 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.